E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Dementia of Alzheimer’s Type [DAT] in subjects with Mini Mental State Examination [MMSE] score 10-19 and Global Deterioration Scale [GDS] score 3-5 and antipsychotics medication during the last 3 months (at least intake at 5 days/week) |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Version | 10.1 |
E.1.2 | Level | LLT |
E.1.2 | Classification code | 10012271 |
E.1.2 | Term | <Manually entered code. Term in E.1.1> |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
The study objective is to assess the potential of reducing the use of antipsychotics in subjects with moderate DAT, treated de novo with memantine.
|
|
E.2.2 | Secondary objectives of the trial |
The secondary efficacy objectives concern the assessment of safety parameters, the impact of memantine and antipsychotics on measures of cognitive functions, behavior, and activities of daily living.
|
|
E.2.3 | Trial contains a sub-study | No |
E.3 | Principal inclusion criteria |
- Current diagnosis of probable AD consistent with NINCDS-ADRDA criteria and with DSM IV TR criteria for DAT (precised in Appendices B and C) - Treatment with typical or atypical antipsychotic medication for at least 5 days/week during the last 3 months prior to the screening visit - If DAT treated with a cholinesterase inhibitor, treatment with a stable dose during the 3 months preceding the screening visit - MMSE score of 10-19 / GDS score of 3-5 - Signed informed consent prior to the initiation of any study specific procedures - Male or female of age ≥ 50 years and <85 years - The subject speaks German as a mother tongue or at least speaks German fluently in order to comply with the study requirements - MRI or CT scan supporting the diagnosis of DAT without indications of any relevant other CNS disorders - Sufficient sight and hearing (a hearing aid is permitted) to enable the performance of study-related procedures and psychometric tests - In the investigator’s opinion, the subject will be capable of completing all study-related activities - If female, subject is at least 2 years post menopausal or surgically sterile |
|
E.4 | Principal exclusion criteria |
- Previous or current treatment with memantine or participation in an investigational study with memantine - Treatment with depot antipsychotics - Treatment with more than 2 antipsychotic drugs at the time of study entry and during 3 months prior to the screening visit - Intake of any medication that is contra-indicated in combination with memantine (precised in SmPC) - Evidence of clinically significant and active pulmonary, gastrointestinal, renal, hepatic, endocrine or cardiovascular system disease (Note, subjects with controlled diabetes and hypertension can be included, provided they do not use unauthorized concomitant medication) - Within 3 months prior to screening clinically significant or currently untreated B12, TSH or folate deficiency (subjects with thyroid disease can be included in the study, provided they are stable and euthyroid) - History of severe drug allergy, or hypersensitivity, or known hypersensitivity to amantadine and lactose - Evidence (including CT/MRI results) of any clinically significant CNS disease other than AD, especially other types of dementia (e.g. vascular type dementia, Lewy-body disease, etc.) - Modified Hachinski Ischemia score > 4 at screening (precised in Appendix D) - Current evidence of clinically significant unstable psychiatric illness (other than symptoms associated with AD) including bipolar or unipolar depression - Lifetime diagnosis of psychotic disorder other than symptoms associated with AD - Cancerous disease (hematological or solid tumor), which is currently under treatment or evidence of active disease - Known or suspected history of alcoholism or drug abuse within the past 2 years - Participation in another clinical study for an investigational medicinal product within the previous 90 days (or 5 half-lives of the investigational medicinal product, whichever is longer) prior to the screening visit or during the study - Any disease or medical treatment that can interfere with the assessment of safety, tolerability or efficacy, according to the investigator’s judgment
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
The primary efficacy endpoint is the maximum dose reduction of antipsychotics from baseline to a post-baseline visit in week 8, 12, 16 or 20, at which the value of the VAS is not substantially worse, compared with the baseline value. Substantially worse is defined a a deterioration of 15 % on the VAS.
|
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | Information not present in EudraCT |
E.6.2 | Prophylaxis | Information not present in EudraCT |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Information not present in EudraCT |
E.6.7 | Pharmacodynamic | Information not present in EudraCT |
E.6.8 | Bioequivalence | Information not present in EudraCT |
E.6.9 | Dose response | Information not present in EudraCT |
E.6.10 | Pharmacogenetic | Information not present in EudraCT |
E.6.11 | Pharmacogenomic | Information not present in EudraCT |
E.6.12 | Pharmacoeconomic | Information not present in EudraCT |
E.6.13 | Others | Information not present in EudraCT |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | Information not present in EudraCT |
E.7.1.1 | First administration to humans | Information not present in EudraCT |
E.7.1.2 | Bioequivalence study | Information not present in EudraCT |
E.7.1.3 | Other | Information not present in EudraCT |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Information not present in EudraCT |
E.7.3 | Therapeutic confirmatory (Phase III) | Information not present in EudraCT |
E.7.4 | Therapeutic use (Phase IV) | Yes |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | Information not present in EudraCT |
E.8.1.2 | Open | Information not present in EudraCT |
E.8.1.3 | Single blind | Information not present in EudraCT |
E.8.1.4 | Double blind | Information not present in EudraCT |
E.8.1.5 | Parallel group | Information not present in EudraCT |
E.8.1.6 | Cross over | Information not present in EudraCT |
E.8.1.7 | Other | No |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | Information not present in EudraCT |
E.8.2.2 | Placebo | Information not present in EudraCT |
E.8.2.3 | Other | Information not present in EudraCT |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.4.1 | Number of sites anticipated in Member State concerned | 25 |
E.8.5 | The trial involves multiple Member States | No |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.7 | Trial has a data monitoring committee | No |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
| |
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | |
E.8.9.1 | In the Member State concerned days | |